You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. The Daily Progress System- A Recovery Support Tool to Reduce Health Disparities in Outpatient Substance Use Treatment

    SBC: COG ANALYTICS, LLC            Topic: 102

    ABSTRACTSubstance use disordersSUDsincluding opioid use disorderscontinue to be one of the most serious public health issues in the USleading to negative physical and mental health problemsfamily disruptionand premature deathAfrican Americans with drug use histories that are under criminal justice supervision are particularly vulnerable to experiencing the negative consequences associated with SUD ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. An Advanced Lung Organomimetic to Reproduce Human Airway Pathophysiology

    SBC: Pneumax, LLC            Topic: 113

    PROJECT SUMMARYThree of top five causes of death in humans globally are lung relatedchronic obstructive pulmonary diseaseCOPDlower respiratory infections and lung cancers collectively account for over eight million deaths annuallyCurrentlyin preclinical settingstatic cell cultures and animal models are the most widely used systems for mechanistic and translational studiesHowevercritical limitation ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Carbidopa, an iron chelator and an ABCG2 inducer, for treatment of gouty arthritis

    SBC: South Plains Biotechnology, Inc            Topic: NIAMS

    Our goal is to evaluate the efficacy of the FDA approved drug Carbidopa for the treatment of gouty arthritis in mouse modelsCarbidopa is used to treat Parkinson s diseasebut always in combination of L DOPAnever alone by itselfGouty arthritis is caused by deposition of monosodium urateMSUcrystals in jointsinitiating inflammation and arthritisInterestinglygout is not always directly related to incre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Granulocyte/Monocyte Precursors to Treat Neutropenia after Cancer Chemotherapy

    SBC: Cord Blood Plus, Inc.            Topic: 102

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to move our product forward toward commercialization by improving the quality of life for breast cancer chemotherapy patientsThis will be achieved by the following Specific AimsAimwill optimize differentiation of GMPs and neutrophil lineages in culture in response to G CSFThis will be assessed by flow cytometry to quantify production of ne ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A novel biodegradable nerve conduit drug delivery device for peripheral nerverepair

    SBC: Microsurgical Innovations Inc            Topic: 999

    Project Summary Nerve injury can occur due to traumachronic compression or disease processes such as diabetes or tumors and have a tremendous socioeconomic impact from loss of work and healthcare costsThere is still a clinical need to improve recovery from nerve injuriesand a new nerve conduit drug delivery device that addresses this clinical need is the focus of the present proposalOur group has ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Continuous real-time fentanyl sensor platform based on smart hydrogels for application in anesthesia

    SBC: Sentiomed, Inc.            Topic: 300

    PROJECT SUMMARY ABSTRACT The opioid fentanyl is administered in millions of procedural sedations every yearIt is very potenthas large interpatient pharmacokinetic variabilityand routinely causes significant respiratory depression if bolused or not titrated judiciouslyDosing and timingcritical for safety and efficacyare presently only possible based on educated guesses and vital signsSedation assoc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Me & You-Tech: A socio-ecological solution to teen dating violence for the digital age.

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    ABSTRACT The goal of thisyear Fast Track STTR is to develop and evaluate a multi levelyouthparentschoolInternet based dating violenceDVprevention programMe andampYou TechMYTforthgrade middle school studentsByth gradeapproximatelyof students will have engaged in a dating relationshipOf thesealmost one third will have perpetrated physical DV and almost two thirds will have perpetrated emotional DVYo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing

    SBC: Bondwell Technologies Inc.            Topic: 400

    Therapeutic antibodies have had a profound impact on treatment of many types of cancer and autoimmune diseasesAs a resultfive of the top ten best selling drugs ofwere therapeutic antibodiesMore than seventy therapeutic antibodies have been approvedand over six hundred antibody based products are in clinical developmentHoweverantibodies are extremely expensive to produceand large amounts of antibod ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIAMS

    Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government